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Hereditary hemorrhagic telangiectasia (HHT) is mechanistically and therapeutically
challenging, not only because of the molecular and cellular perturbations that generate
vascular abnormalities, but also the modifications to circulatory physiology that result,
and are likely to exacerbate vascular injury. First, most HHT patients have visceral
arteriovenous malformations (AVMs). Significant visceral AVMs reduce the systemic
vascular resistance: supra-normal cardiac outputs are required to maintain arterial
blood pressure, and may result in significant pulmonary venous hypertension. Secondly,
bleeding from nasal and gastrointestinal telangiectasia leads to iron losses of such
magnitude that in most cases, diet is insufficient to meet the ‘hemorrhage adjusted
iron requirement.’ Resultant iron deficiency restricts erythropoiesis, leading to anemia
and further increases in cardiac output. Low iron levels are also associated with venous
and arterial thromboses, elevated Factor VIII, and increased platelet aggregation to
circulating 5HT (serotonin). Third, recent data highlight that reduced oxygenation of
blood due to pulmonary AVMs results in a graded erythrocytotic response to maintain
arterial oxygen content, and higher stroke volumes and/or heart rates to maintain oxygen
delivery. Finally, HHT-independent factors such as diet, pregnancy, sepsis, and other
intercurrent illnesses also influence vascular structures, hemorrhage, and iron handling
in HHT patients. These considerations emphasize the complexity of mechanisms
that impact on vascular structures in HHT, and also offer opportunities for targeted
therapeutic approaches.
Keywords: anemia, cardiac output, hypoxia, hemorrhage, iron deficiency, paradoxical emboli, pulmonary
hypertension, venous thromboemboli
Introduction
Hereditary hemorrhagic telangiectasia (HHT) results from a single mutation in a causative gene
such as endoglin, ACVRL1 (encoding ALK-1), or SMAD4. The hallmark of HHT is the presence
of arteriovenous malformations (AVMs), and smaller telangiectatic vessels. Additional pheno-
typic patterns are recognized in smaller numbers of patients (Shovlin, 2010; McDonald et al.,
2011).
Hereditary hemorrhagic telangiectasia severity is usually assessed with reference to:
• the presence of vascular abnormalities at particular sites;
• their severity (by anatomic or physiologic measurements);
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• hemorrhage, and/or
• organ-speciﬁc consequences due to blood bypassing critical
capillary beds.
Recent data have begun to illuminate a pattern of marked envi-
ronmental modiﬁcation of speciﬁc aspects of the HHT pheno-
type, for example in relation to blood ﬂow, bleeding, and throm-
boses. Many ‘environmental’ modiﬁers can be consequences of
the HHT phenotype itself.
This mini review focuses on secondary and tertiary conse-
quences of HHT vascular structures. These contribute to the
full clinico-pathologic spectrum of HHT, and are relevant to
angiogenic, developmental, and injury considerations presented
elsewhere in this series.
Systemic AVMs and Cardiac Output
Systemic AVMs are one of the classical pathologies associ-
ated with high cardiac output states (Mehta and Dubrey, 2009;
Figure 1), when cardiac index (cardiac output/body surface area)
exceeds 3.9 L/min/m2 (Anand and Florea, 2001). Reduced sys-
temic vascular resistance due to the AVMs leads to a fall in
arterial blood pressure. Resultant activation of sympathetic and
neurohormonal systems increase cardiac output and maintain
vital organ perfusion at the expense of salt and water reten-
tion (Anand and Florea, 2001; Mehta and Dubrey, 2009). The
increases in cardiac output that are needed to preserve arterial
blood pressure in the face of severe reductions in systemic vas-
cular resistance may exceed the pump capacity of healthy hearts,
leading to high output cardiac failure (Anand and Florea, 2001;
Mehta and Dubrey, 2009). High left atrial ﬁlling pressures lead
to pulmonary venous hypertension (Anand and Florea, 2001;
Mehta and Dubrey, 2009).
Relevance to the HHT Phenotype
All vessels, including abnormal HHT vascular structures, adapt
to the volume and pressure of blood ﬂowing through them.
HHT vessels do not behave normally, for example, AVMs do
not display the usual adaptation to optimal arterial wall thick-
ness/ lumen radius ratios to minimize wall stress (Owens, 2010).
Within speciﬁc vascular beds, increased ﬂow modiﬁes vascular
structures. In HHT, this is best exempliﬁed by the dilated feed-
ing arteries and draining veins associated with pulmonary AVMs
(Figure 2). These regress once pulmonary AVMs are embolized
and such regression is one of the hallmarks of successful obliter-
ation of the PAVM sacs.
More widely, higher circulating blood volumes are predicted
to impact on HHT vascular structures. Multiple HHT series
and case reports indicate that in women with HHT, preg-
nancy can result in the development of new telangiectasia/AVMs,
enlargement of existing AVMs, and hemorrhage which may be
life-threatening (Ference et al., 1994; Shovlin et al., 1995, 2008;
de Gussem et al., 2014).
Relevance to HHT Clinical Trials
Hemodynamic parameters are increasingly used to evaluate treat-
ment eﬃcacy in HHT clinical trials. Reduction in cardiac index,
measured by echocardiography, was the primary eﬃcacy crite-
rion in an evaluation of Bevacizumab in 25 patients with severe
FIGURE 1 | Pathophysiology of high cardiac output states. The cardiac
output is the volume of blood ejected each minute by a ventricle, and the
product of stroke volume, and heart rate/minute. Systemic vascular resistance is
defined by meanarterial pressure−mean right atrial pressurecardiac output . For further details of clinical
states that reduce systemic vascular resistance, see Anand et al., 1993;
Anand and Florea, 2001; Mehta and Dubrey, 2009. Abbreviations: RAAS,
renin–angiotensin–aldosterone system. Note the potential positive feedback
loops influencing HHT vascular structures.
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FIGURE 2 | Cartoon of usual behavior of macroscopic, discrete
PAVMs pre and post embolization. (Left) Preferential blood flow through
pulmonary arteriovenous malformation (AVM) sacs (red border) leads to
reduced perfusion of non-PAVM associated arteries (gray), dilatation of
feeding arteries that commonly appear as second or third order vessels;
and dilatation/early filling of draining veins. Centre left: immediately
following embolization of all feeding arteries, blood flow ceases through the
pulmonary AVM, and is redirected to normal arteries. Surprisingly it appears
very rare for sac thrombus to embolise before organization. Centre right
and far right: over subsequent months, assuming feeding arteries remain
occluded and the pulmonary AVM does not acquire new feeding arteries,
organization, and remodeling leads to regression of the sac, and
normalization of diameters of former feeding arteries/draining veins (For
patient images, see Howard et al., 2014).
hepatic AVMs: 6 months treatment reduced the cardiac index
from 5.1 L/min/m2 to 4.1 L/min/m2, and pulmonary hyper-
tension regressed in ﬁve cases (Dupuis-Girod et al., 2012). In a
separate study evaluating liver transplantation for severe hep-
atic AVMs, the mean cardiac index fell from 5.75 L/min/m2 to
3.4 L/min/m2 (Dupuis-Girod et al., 2010).
Hemorrhage, Iron Deficiency, and
Anemia
Patients with HHT are prone to iron deﬁciency because of
chronic and repeated blood losses from nasal and gastrointestinal
telangiectasia. HHT telangiectasia have fragile walls, often lined
by a single endothelial layer with no smooth muscle cells or per-
icytes, despite acting as conduits for blood at arterial pressure
(Braverman et al., 1990).
Anemia develops because iron is required to synthe-
size hemoglobin. Iron handling is generally normal in HHT
(Finnamore et al., 2013)- if total body iron stores fall, circu-
lating levels of hepcidin also fall, facilitating iron absorption
through the gastrointestinal tract, and iron recycling from
hepatocytes and senescent erythrocytes (Ganz, 2013). Over
time, if iron intake remains insuﬃcient for needs, body stores
are exhausted, leading to iron deﬁciency. The ‘hemorrhage
adjusted iron requirement’ helps predict when iron deﬁciency
is likely to occur, if additional iron supplements are not given
(Finnamore et al., 2013).
Additional iron can be ingested orally, and/or administered
through iron infusions. However, chronic anemia of a severity
suﬃcient to require red cell (blood) transfusions is common in
HHT: One survey reported that 243/915 (26.6%) HHT patients
had received a blood transfusion due to epistaxis (nosebleeds,
Hoag et al., 2010), and another, that 39/220 (17.7%) patients had
required blood transfusions on at least 10 separate occasions
(Elphick and Shovlin, 2014).
Limiting HHT blood losses reduces the amount of iron
required to avoid iron deﬁciency and anemia. Strategies include
classical otorhinolaryngology surgery; limitation of epistaxis
triggers such as hypertension (Purkey et al., 2014), allergic
rhinitis/sinusitis (Purkey et al., 2014), dietary (Silva et al., 2013;
Elphick and Shovlin, 2014), and drug precipitants (Folz et al.,
2005; Devlin et al., 2013; Purkey et al., 2014); and newer med-
ical treatments. Recent attention has focused on hormonal
manipulations (Yaniv et al., 2009; Albiñana et al., 2010), thalido-
mide (Lebrin et al., 2010), tranexamic acid (Gaillard et al.,
2014: Geisthoﬀ et al., 2014), and intranasal Bevacizumab
(Karnezis and Davidson, 2012; Dupuis-Girod et al., 2014;
Riss et al., 2014). There are a number of reports and small,
uncontrolled case series reporting the beneﬁts of systemic
bevacizumab and other agents, though randomized trials are as
yet lacking.
Anemia, Iron, and Cardiac Output
Chronic anemia leads to reduced systemic vascular resis-
tance and high cardiac outputs in the general popula-
tion (Porter and Watson, 1953; Anand et al., 1993; Hébert et al.,
2004). Treatment of iron deﬁciency has beneﬁcial eﬀects in gen-
eral heart failure (Ponikowski et al., 2014): beneﬁts observed in
the absence of anemia are attributed to the major iron require-
ments of tissues with high-energy demands such as the heart and
skeletal muscle (Cohen-Solal et al., 2014).
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For patients with HHT and hepatic AVMs, the largest
prospective series identiﬁed iron deﬁciency anemia as the
most common precipitant of high output cardiac failure
(Buscarini et al., 2011). In the hepatic AVM-Bevacizumab trial
(Dupuis-Girod et al., 2012), the relevance of reduced epistaxis
(from 221 to 43 min/month), and modest hemoglobin increase,
is not yet known.
Thromboses in a Hemorrhagic Condition
Despite their frequent hemorrhages, HHT patients are at risk
of deep venous thromboses and pulmonary emboli, i.e., venous
thromboemboli (VTE; Shovlin et al., 2007; Livesey et al., 2012).
A study of 609 consecutive patients with HHT demonstrated
an ∼2.5-fold increase in VTE risk with low serum iron
(Livesey et al., 2012). The association was evident in “healthy”
HHT patients in the community, and appeared to be mediated
through elevated coagulation factor VIII (Livesey et al., 2012),
which is a well-established risk factor for ﬁrst and recurrent VTE
in the general population (Kyrle et al., 2000; Cosmi et al., 2008;
Vormittag et al., 2009; Pabinger et al., 2013; Kovac et al., 2015).
Approximately 50% of HHT patients have pulmonary AVMs
and are also at risk of paradoxical embolic strokes because sys-
temic venous blood can bypass the normal pulmonary capillary
ﬁlter (Shovlin, 2014a; Shovlin et al., 2014). In a study published
15 years ago, 34/67 patients with pulmonary AVMs had evidence
of cerebral infarcts on MRI scans (Moussouttas et al., 2000).
Myocardial infarcts are also attributed to paradoxical emboli in
HHT patients with pulmonary AVMs (Clark et al., 2013). In a
series of 497 consecutive patients with CT-proven pulmonary
AVMs due to HHT, a low serum iron was a strong risk factor
for a clinical ischemic stroke: for the same pulmonary AVMs,
the stroke risk would approximately double with serum iron
6 µmol/L compared to mid-normal range (Shovlin et al., 2014).
Platelet studies conﬁrmed overlooked data that iron deﬁciency is
associated with exuberant platelet aggregation to 5HT/serotonin
(Woods et al., 1977; Shovlin, 2014b; Shovlin et al., 2014).
Pulmonary AVMs and Hypoxemia
Pulmonary AVMs lead to low oxygen levels in the blood (hypox-
emia) because they allow a fraction of pulmonary arterial blood
to bypass the pulmonary capillary bed and hence gas exchange
(Shovlin, 2014a).
However, in the chronic state, individuals with adequate iron
supplies maintain their total arterial oxygen content (CaO2) by
increasing hemoglobin using an apparently graded erythrocy-
totic response (Santhirapala et al., 2014a). Similar ﬁndings are
observed in the general population at altitude, when compen-
satory responses can be evident within 7 days (Ryan et al., 2014).
For pulmonary AVM patients, compensations were shown to be
less successful if iron deﬁciency was present (Santhirapala et al.,
2014a). After successful embolization treatment of pulmonary
AVMs, hematologic compensatory responses are lost. Patients
appeared to reset to the same CaO2, unless there was an interim
correction of iron deﬁciency (Santhirapala et al., 2014a).
Pulmonary AVMs also result in high cardiac outputs,
with exact mechanisms diﬀering to systemic AVMs, due
to the lower blood oxygenation. At rest and on exercise,
increased stroke volumes are utilized (Whyte et al., 1993;
Howard et al., 2014; Vorselaars et al., 2014). The heart rate nor-
mally increases on standing, but in patients with pulmonary
AVMs and a sudden drop in SaO2 on standing, the heart rate
increases further, inversely proportional to the fall in SaO2
(Santhirapala et al., 2014b). After correction of hypoxemia by
embolization treatments, hemodynamic compensatory responses
are lost (Vorselaars et al., 2014).
The loss of both hematologic and hemodynamic compen-
satory responses following embolization helps explain why
exercise capacity, and oxygen consumption are frequently
no higher after embolization, despite substantial increases in
SaO2 (Howard et al., 2014; Shovlin, 2014a; Yasuda et al., 2015).
HHT-Independent Factors
Hemodynamics
HHT-independent causes of reduced systemic vascular resistance
and high cardiac outputs include exercise, pyrexia, other forms
of anemia, pregnancy, sepsis, liver cirrhosis, and use of systemic
vasodilating agents (Anand and Florea, 2001; Mehta and Dubrey,
2009).
Hemorrhage
‘Hemorrhagic’ iron losses occur in multiple settings including
menstruation, blood donation, and surgery. All lead to greater
iron requirements for the HHT patient (Finnamore et al., 2013).
Concurrent coagulation disorders, drugs (Devlin et al., 2013),
and even dietary agents (Silva et al., 2013; Elphick and Shovlin,
2014) are reported to increase hemorrhagic losses in HHT.
Iron Handling
Iron handling is controlled by hepcidin, a liver-synthesized pep-
tide hormone which is normally expressed at lower levels in
iron deﬁciency, facilitating gastrointestinal iron absorption, and
iron recycling from macrophages and hepatocytes, through the
iron transporter ferroportin (Ganz, 2013). Active bleeding further
represses hepcidin expression via erythroferrone (Kautz et al.,
2014). However, inﬂammatory and other chronic disease states
often result in inappropriately high hepcidin levels, and failure to
absorb oral iron irrespective of doses ingested (Ganz, 2013). In
HHT, the hepcidin/ferroportin axis appears to operate normally:
generally, hepcidin levels are appropriately low in iron deﬁciency,
displaying similar relationships to ferritin as for healthy controls
(Finnamore et al., 2013). However, intercurrent illnesses are pre-
dicted to perturb these normal relationships, and aggravate iron
deﬁciency.
Thromboses
A description of the potential causes of pathological venous and
arterial thromboses is beyond the scope of this text. Surprisingly,
of 379 patients with HHT who received antiplatelet or anticoag-
ulant therapy (usually to treat or prevent VTE, ischemic strokes
Frontiers in Genetics | www.frontiersin.org 4 April 2015 | Volume 6 | Article 101
Shovlin HHT and circulatory modifiers
or cardiac conditions), 153 (40.4%) reported no change in their
nosebleeds, and 9 (2.4%) reported an improvement (Devlin et al.,
2013).
Conversely, tamoxifen, raloxifene, tranexamic acid, thalido-
mide, and Bevacizumab that are used to treat HHT-related
bleeding are also recognized in certain circumstances to expose
patients to enhanced risk of thrombosis. To date, thrombotic
events have not been reported in the HHT clinical trials, but a
history of previous thrombosis is considered a contraindication
to their use in HHT.
Conclusion
From a mechanistic perspective, these circulatory contribu-
tors to the phenotype in HHT increase the complexity of the
disorder. New paradigms are added to current research foci,
and new ontology groupings to potential HHT modiﬁer gene
lists. Therapeutic targeting of hemorrhage and visceral AVMs
in HHT remain major challenges. The states discussed above
remind of the potential value of concurrent, simple treat-
ment approaches, particularly preventing or correcting iron
deﬁciency.
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